2022-11-14
[HONG KONG, November 14, 2022] The second Asia Summit on Global Health was held in Hong Kong on November 10, 2022, co-organised with the Government of the Hong Kong Special Administrative Region (HKSAR) and the 13th Hong Kong International Medical and Healthcare Fair. John Lee, Hong Kong SAR (HKSAR) Chief Executive, spoke at the summit’s opening ceremony, along with Margaret Fong, Executive Director of the HKTDC, Zsuzsanna Jakab, Deputy Director-General of World Health Organization (WHO); and Cao Xuetao, Vice-Minister of the National Health Commission of the People's Republic of China.

With the theme of “Charting a New Course in Healthcare through Collaboration”, more than 70 speakers from Japan, South Korea, Israel and other countries in the field of healthcare, representatives of international organizations, representatives of business circles and heads of relevant fields delivered speeches. More than 80 business leaders in the healthcare industry, scientific research professionals, healthcare officials and professional service providers, as well as more than 20,000 participants both in-person and online session discussed the opportunities and development of the global healthcare industry.

In addition, Dr. Kane Qi, Chief Commercial Officer of GBB, attended the ASGH - Shanghai-Hong Kong Cooperation Transition and 2022 Shanghai-Hong Kong Industry-Medical Integration Conference, and gave a speech entitled "Accelerating Bioprocessing Development through AI Technology".

Asia Summit on Global Health (ASGH) brings together all the stakeholders - from healthcare experts to renowned academia and influential business leaders, together with key industry players, innovative start-ups, investors and policymakers from around the world to exchange insights, explore opportunities and collaborate on the diverse and dynamic healthcare sector.

Great Bay Bio’s AlfaCell Delivers Average Titer Above 6.9 g/L Across Client Projects, with RCB Completed in Just 1.5 Months
2026-03-27

Great Bay Bio Recognized in the Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program, Receiving Further Authoritative Recognition for AI-Enabled Bioprocess Innovation
2026-03-26

Great Bay Bio’s CHO-K1 Catalog Medium AlfaMedX- K1 (Growth Factor–Free) Achieves FDA DMF Filing
2026-03-09